KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) EBIAT (2016 - 2025)

Pfizer (PFE) has disclosed EBIAT for 17 consecutive years, with -$1.6 billion as the latest value for Q4 2025.

  • Quarterly EBIAT changed N/A to -$1.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $7.8 billion for FY2025, 2.97% down from the prior year.
  • EBIAT for Q4 2025 was -$1.6 billion at Pfizer, down from $3.6 billion in the prior quarter.
  • The five-year high for EBIAT was $9.9 billion in Q3 2022, with the low at -$2.4 billion in Q4 2023.
  • Average EBIAT over 5 years is $3.1 billion, with a median of $3.0 billion recorded in 2025.
  • The sharpest move saw EBIAT crashed 127.74% in 2023, then skyrocketed 6997.56% in 2025.
  • Over 5 years, EBIAT stood at $590.0 million in 2021, then plummeted by 61.86% to $225.0 million in 2022, then plummeted by 79.11% to $47.0 million in 2023, then soared by 9400.0% to $4.5 billion in 2024, then tumbled by 135.99% to -$1.6 billion in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$1.6 billion, $3.6 billion, and $2.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.